Latest Breaking News On - Cedrik britten - Page 1 : comparemela.com

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

University hospitalUnited statesCedrik brittenSabrina schecherInstagramand linkedinImmatic actengineCharlotte spitzMartin wermkeSociety for melanoma researchExchange commissionTrophic communicationsInternational congressUniversity hospital dresdenMelanoma researchCell therapyCoordinating investigator

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesImmatic actengineCedrik brittenIhre chancenSabrina schecherIndiens wirtschaftInstagramand linkedinCharlotte spitzTrophic communicationsRegenerative medicine advanced therapyBiologics evaluationChief medical officerCentury cures actFast trackAll immaticStem cell therapeutics research laboratory

Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesCedrik brittenCharlotte spitzAnja heuerEuropean society for medical oncologyTrophic communicationsCorporate communicationsInitiates phaseAdvanced solidChief medical officerEuropean societyMedical oncologyAdoptive cell therapiesLooking statementsInvestor relations

Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

Company to host conference calltoday, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203

United statesUniversity hospitalMartin wermkeCedrik brittenAnja heuerInstagramand linkedinCharlotte spitzImmatic actengineUniversity hospital dresdenEuropean central bankResearch institute of texasCorporate communicationsTrophic communicationsCoordinating investigatorChief medical officerSafety monitoring board

Immatics (IMTX) Reports Interim Clinical Data from Ongoing Phase 1b trial of ACTengine IMA203 TCR-T

Immatics (IMTX) Reports Interim Clinical Data from Ongoing Phase 1b trial of ACTengine IMA203 TCR-T
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cedrik brittenAnja heuerCharlotte spitzImmatic actengineMartin wermkeTrophic communicationsUniversity hospital dresdenCorporate communicationsResearch institute of texasEuropean central bankCoordinating investigatorChief medical officerSafety monitoring boardOverall responseNeuroendocrine tumorBest overall